CAR T-Cell Eligibility and Referral in DLBCL

In this segment, Dr. Mark Dailey, Dr. Caron A. Jacobson, and NP Stefanie Sigmund introduce the challenges of coordinating chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large B-cell lymphoma (DLBCL), particularly those who must travel long distances to specialized treatment centers. Dr. Jacobson discusses misconceptions surrounding CAR T-cell eligibility, emphasizing that advanced age and certain comorbidities should not automatically exclude patients from evaluation. She reviews patient groups who may be considered for CAR T-cell therapy in the second-line setting, including those with primary refractory disease or early relapse, as well as patients with relapsed or refractory disease in later lines. The discussion highlights the importance of timely referrals, early engagement with CAR T-cell centers, and considering clinical trial opportunities for high-risk patients. Dr. Dailey also shares the community oncology perspective on referring patients promptly and preparing them and their families for the potential treatment journey.